Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of driver mutations in lung cancer: first step in personalized cancer.

Targeted oncology - 1 Mar 2013

Planchard David

Abstract excerpt

Non-small cell lung cancer (NSCLC) has recently been associated with interesting molecular characteristics that have important implications in carcinogenesis and response to targeted therapies. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abrogate cell signaling that perpetuates cancer progression. For instance, several molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ALK gene
Share to EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EML4 gene

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Precision Medicine

Source

Identifiers

PMID: 23371030
DOI: 10.1007/s11523-013-0263-z

Genes

ALK
EGFR
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of driver mutations in lung cancer: first step in personalized cancer.PMID 23371030Read ↗

Oncogenic driver mutations in lung cancerSemantic proximity Read ↗

Personalized targeted therapy for lung cancer.Semantic proximity Read ↗

Molecular pathology of lung cancer: key to personalized medicine.Semantic proximity Read ↗

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.Semantic proximity Read ↗

Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.Semantic proximity Read ↗

Recent Advances in Personalized Lung Cancer MedicineSemantic proximity Read ↗

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung CancerSemantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.Semantic proximity Read ↗

Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.